The 2 references in paper Anas Younes , Anas Younes, Dirk Huebner , Dirk Huebner, Joseph M. Connors , Joseph M. Connors, Megan M. O'Meara , Megan M. o'Meara, Michelle Fanale , Michelle Fanale, Naomi N. Hunder , Naomi N. Hunder, Stephen M. Ansell , Stephen M. Ansell, Steven I. Park , Steven I. Park (2015) “БРЕНТУКСИМАБ ВЕДОТИН В КОМБИНАЦИИ С ABVD ИЛИ AVD ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ВПЕРВЫЕ ДИАГНОСТИРОВАННОЙ ЛИМФОМОЙ ХОДЖКИНА: ОТКРЫТОЕ ИССЛЕДОВАНИЕ I ФАЗЫ С ЭСКАЛАЦИЕЙ ДОЗЫ // BRENTUXIMAB VEDOTIN COMBINED WITH ABVD OR AVD FOR PATIENTS WITH NEWLY DIAGNOSED HODGKIN'S LYMPHOMA: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY” / spz:neicon:modonc:y:2014:i:3:p:8-15

Harel S, Ferme C, Poirot C. Management of fertility in patients treated for Hodgkin’s lymphoma. Haematolog 2011; 96: 1692–9.
(check this in PDF content)
Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 6400–8. 3 Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F] fluoro-2deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-sta
(check this in PDF content)